For a long time, I thought advocacy meant surviving the next appointment. I thought it meant learning how to explain my pain better, how to prepare for another referral visit, how to justify why I...

Editor's Note: This article was originally published on April 10, 2026, by Lupus Colorado and is republished here with permission. The Patient Affordability Roundtable discussed in this piece was...

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

Rising employer premiums averaging 9.5% erode wages, forcing workers to delay care.

Q1 2026 Watch: HCV/HIV co-infection treatment access under evolving federal and state policies.

Enhanced ACA subsidies expired Jan 1; Senate framework proposes two-year extension with restrictions.

CANN marks 30th anniversary with expanded partnerships and cross-condition advocacy evolution.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Clade I mpox emergence reveals structural collapse in U.S. disease surveillance and public health response infrastructure.

Miss Major Griffin-Gracy's legacy demonstrates solidarity's power in building healthcare justice and community leadership.

Government shutdown disrupts grant payments to community health centers and crisis service providers, threatening vulnerable population access.

RFK Jr's dismantling of CDC scientific leadership replaces expertise with anti-vaccine ideology and predetermined policy conclusions.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

RFK Jr's Administration for a Healthy America proposes to dismantle infectious disease capacity while emphasizing unproven chronic disease theories.

Caregiving infrastructure supports health equity and healthcare outcomes, requiring policy investment in caregiving infrastructure.

Antibiotic-resistant bacteria threaten basic medical procedures while drug development incentives prove inadequate for innovation.

Federal spending cuts disproportionately impact vulnerable populations relying on safety-net programs and community health services.

Deteriorating public health surveillance capacity creates blind spots for emerging disease threats and health disparities.

Declining vaccination rates and policy challenges create vulnerability to vaccine-preventable diseases and epidemic risk.